Cost

GLP-1 Budget Plan: How to Lower Monthly Costs

GLP-1 Companion · 9 min read

A GLP-1 budget plan fails when it only asks what the medication costs this month. The better question is what the full plan costs for the next 6-12 months: clinical visits, labs, pharmacy fills, shipping, refills, dose changes, savings-card rules, and the backup option if insurance says no.

My position: do not start a paid GLP-1 program until you can write the monthly number on one page. A cheap first fill is not a budget if the second fill depends on a coupon you do not understand.

List Price vs. Out-of-Pocket Reality

The list price of a medication (also called the wholesale acquisition cost or WAC) is the manufacturer's published price before any discounts, rebates, or insurance negotiations. It is rarely the price anyone actually pays. Between manufacturer savings programs, insurance negotiated rates, pharmacy benefit manager rebates, and coupons, most commercially insured patients pay a fraction of list price. The challenge is knowing which programs you qualify for and stacking them strategically.

Manufacturer Savings Programs

Both Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) offer manufacturer savings programs for commercially insured patients. These are the single most impactful cost reduction tools available and should be the first stop for any GLP-1 patient.

• Novo Nordisk Ozempic Savings Offer: Eligible commercially insured patients may pay as little as $25/month. Not valid for Medicare, Medicaid, or the uninsured.
• Novo Nordisk WeGovy Savings Offer: Commercially insured patients may pay $0 for the first month and a reduced monthly out-of-pocket in subsequent months (approximately $200/month maximum in many scenarios). Not valid with federal insurance programs.
• Eli Lilly Mounjaro Savings Card: Eligible commercially insured patients may pay approximately $25–35/month. Requires a valid Type 2 diabetes diagnosis. Not valid for Medicare/Medicaid.
• Eli Lilly Zepbound Savings Program: Commercially insured patients eligible for obesity treatment may pay as little as $25/month. Not valid with federal insurance programs.

GoodRx, SingleCare, and Pharmacy Coupons

GoodRx and SingleCare aggregate pharmacy discount coupons that are sometimes lower than insurance copays or manufacturer savings program prices. These are particularly useful for patients without commercial insurance, those whose plans do not cover GLP-1s, or when the coupon price beats the insurance copay for a given month.

As of early 2026, GoodRx prices for GLP-1 medications vary significantly by pharmacy and location but typically range from $850–$950 for a 4-week supply of brand-name semaglutide or tirzepatide — meaningful discounts from list price but still substantial out-of-pocket costs for uninsured patients. GoodRx is most valuable as a secondary tool when insurance coverage is denied or during coverage gaps.

Pharmacy Shopping: Prices Vary More Than You Think

Pharmacy prices for the same medication with the same coupon can vary by hundreds of dollars per month. Independent pharmacies, Costco Pharmacy, and Sam's Club Pharmacy frequently offer prices meaningfully below large chain pharmacies. Mail-order pharmacies through insurance plans typically offer the lowest cost for insured patients, often including a 90-day supply option.

• Use GoodRx to compare prices at multiple pharmacies within your zip code before filling.
• Call your insurance's preferred mail-order pharmacy — many plans offer lower specialty drug copays for 90-day mail-order supplies.
• Costco Pharmacy does not require membership to use the pharmacy and frequently offers competitive prices on specialty medications.
• Independent compounding pharmacies are no longer a legal source of FDA-approved semaglutide or tirzepatide — FDA enforcement resolved the compounding authorization in early 2025.

90-Day Supply Savings

Many insurance plans offer lower per-unit costs for 90-day supplies compared to monthly 30-day fills. For patients on stable doses, requesting a 90-day prescription and using a mail-order pharmacy can reduce costs by 10–25% compared to monthly fills at a retail pharmacy. This requires being on a stable dose — dose escalation periods require more frequent adjustments and may not be compatible with 90-day supplies.

Telehealth vs. In-Person Visit Costs

Telehealth platforms (Ro, Hims & Hers, Found, and similar) have dramatically expanded access to GLP-1 prescriptions. A telehealth consultation for a GLP-1 prescription typically costs $50–$150 for an initial visit and $25–$75 for follow-ups, compared to $150–$350 for an in-person endocrinologist or obesity medicine specialist visit without insurance.

Telehealth platforms also sometimes bundle the prescription with medication fulfillment through partner pharmacies at negotiated rates. The tradeoff is less comprehensive metabolic monitoring compared to specialist care — an important consideration for patients with complex diabetes management or multiple comorbidities.

Oral GLP-1 Options: A Potential Budget Game-Changer

The oral GLP-1 landscape is evolving rapidly. Rybelsus (oral semaglutide at 3 mg, 7 mg, and 14 mg doses) has been available since 2019 for Type 2 diabetes treatment but is less effective for weight loss than injectable semaglutide. The more significant development is orforglipron, a small-molecule oral GLP-1 receptor agonist developed by Eli Lilly.

Orforglipron received FDA approval in 2025 and is expected to carry a substantially lower list price than injectable GLP-1s — industry analyses project a monthly cost in the $200–$400 range before insurance, and some estimates suggest post-insurance costs as low as $25/month for eligible patients. Oral administration eliminates injection-related barriers and may offer better insurance coverage as generic formulations become viable in coming years.

Realistic Monthly Cost Scenarios

The following scenarios illustrate typical actual monthly costs in 2026 for different insurance situations. These are estimates — individual costs depend on specific insurance plan terms, pharmacy choice, and applicable savings programs.

• Commercially insured, GLP-1 covered, manufacturer savings card: $25–$50/month out-of-pocket (most favorable scenario).
• Commercially insured, GLP-1 covered, no savings card: $100–$300/month depending on deductible, copay tier, and plan terms.
• Commercially insured, GLP-1 NOT covered: $850–$1,050/month with GoodRx discount only, or $200–$400/month for orforglipron once broadly available.
• Medicare Part D: Coverage depends on the specific plan. Under the Inflation Reduction Act provisions phasing in through 2026, some Medicare plans now cover obesity medications; check your specific plan's formulary.
• Medicaid: Coverage varies by state. Several states have expanded Medicaid coverage for obesity medications following CMS guidance updates in 2024.
• Uninsured, patient assistance program: $0 for eligible patients under Lilly Cares Foundation or NovoCare (income limits apply — typically under 400–600% of federal poverty level).

Income-Based Programs for Uninsured Patients

Both Novo Nordisk and Eli Lilly operate patient assistance programs for uninsured patients who meet income eligibility criteria. These programs provide medication at no cost or significantly reduced cost for patients who qualify.

• NovoCare Patient Assistance Program: For uninsured patients with income at or below 400% of the federal poverty level (approximately $60,000 for a single person in 2026). Apply at novonordisk-us.com/novocare.
• Lilly Cares Foundation: For uninsured or underinsured patients with income at or below 400% of the federal poverty level. Covers Mounjaro and Zepbound. Apply at lillycares.com.
• NeedyMeds.org: A nonprofit database of all available patient assistance programs, including state-level pharmaceutical assistance programs that may provide additional support.
• RxAssist: Another comprehensive database of PAPs maintained by pharmaceutical manufacturers, often with current eligibility criteria and application links.

Key Takeaways

• Manufacturer savings cards are the most impactful cost reduction tool for commercially insured patients — enroll before or when filling your first prescription.
• GoodRx and pharmacy shopping can reduce costs when insurance does not cover GLP-1s.
• A 90-day mail-order supply can reduce per-dose costs by 10–25% for patients on stable doses.
• Telehealth platforms offer lower consultation costs than in-person specialist visits.
• Oral GLP-1 options like orforglipron represent a potentially lower-cost alternative as they gain market penetration.
• Uninsured patients may qualify for free medication through manufacturer patient assistance programs.

The practical buyer move: compare insurance, local clinician, assistance-program, and telehealth partner routes before committing. If a provider cannot explain the total cost beyond month one, keep looking.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.